Intravenous pretreatment with magnolol protects myocardium against stunning.
Magnolol, an antioxidant, has been reported to possess various protective effects on the cardiovascular system. However, its effect on myocardial stunning has not been elucidated. The purpose of this study was to investigate the antistunning effect of magnolol by evaluating the recovery of regional myocardial function after 10-minute coronary artery occlusion in anesthetized, open-chest rabbits. There was no significant hemodynamic change after intravenous infusion of magnolol. Systolic wall thickening fraction (WThF) measured with an epicardial Doppler sensor in animals pretreated with normal saline and vehicle solution remained significantly depressed (60 +/- 7% and 77 +/- 4% of baseline WThF, respectively) 3 hours after coronary artery reperfusion (CAR). Pretreatment with magnolol (10(-7) and 10(-6) g/kg, intravenous infusion) significantly enhanced the recovery of systolic wall thickening fraction (98 +/- 1 and 99 +/- 1% of baseline WThF, respectively) 60 minutes after CAR. This study demonstrated that intravenous pretreatment with magnolol protected myocardium against stunning.
Huang
C H
CH
Department of Surgery, Veterans General Hospital, Taipei, Taiwan, R.O.C.
Hong
C Y
CY
Tsai
S K
SK
Lai
S T
ST
Weng
Z C
ZC
Chih
C L
CL
Hsieh
Y H
YH
D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000494:pharmacology*; D000975:Antioxidants / Q000008:administration & dosage / Q000494:pharmacology*; D001145:Arrhythmias, Cardiac / Q000503:physiopathology; D001713:Biphenyl Compounds / Q000008:administration & dosage / Q000494:pharmacology*; D006321:Heart / Q000187:drug effects* / Q000503:physiopathology; D007262:Infusions, Intravenous; D017705:Lignans; D008297:Male; D017682:Myocardial Stunning / Q000517:prevention & control*; D011817:Rabbits
D000889:Anti-Arrhythmia Agents; D000975:Antioxidants; D001713:Biphenyl Compounds; D017705:Lignans; C005498:magnolol